Jill Elaine Wykosky, PhD
Section of Human Carcinogenesis
Laboratory of Tumor Biology
Ludwig Institute for Cancer Research
La Jolla, CA
Ph.D., Molecular Medicine, 2003 -2008
Wake Forest University
School of Medicine
Areas of specialization: Cancer Biology, Brain Tumor Biology
B.S., Microbiology with Honors in Biological Sciences, 1999-2003, Summa cum Laude
Related area, Chemistry
University of Pittsburgh, Pittsburgh, Pennsylvania,
Certified, Conceptual Foundations of Medicine
The oncogenic role of signal transduction mediated by protein or lipid phosphatases as well as the differences between the signaling effected by oncogenic mutant receptors and their normal wild-type counterparts.
Wykosky J and Debinski W. Molecular Targeting of IL-13R2 and EphA2 Receptor in GBM. In: E.G. Van Meir (Ed.) CNS Cancer: Models, Prognostic Factors, and Targets. Dec 2008. Springer.
Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, and Debinski W. Soluble, monomeric ephrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene, advance online publication, 15 September 2008.
Wykosky J and Debinski W. Function and therapeutic targeting of the EphA2/ephrinA1 system in solid tumors. Molecular Cancer Research, 2008, In press.
Wykosky J, Gibo DM, Stanton C, and Debinski W. IL-13 Receptor alpha 2, EphA2, and Fra-1 as molecular denominators of high-grade astrocytomas. Clinical Cancer Research 14(1), 199-208, 2008.
Wykosky J, Gibo DM, and Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. MolecularCancer Therapeutics 6(12): 3208-3218, 2007.
For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine.
NRSA Pre-doctoral fellowship: NINDS, 2006-2008
F31 NSO55533-01 “EphA2: Function and Targeting in Malignant Gliomas”